<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964583</url>
  </required_header>
  <id_info>
    <org_study_id>2020-785-138</org_study_id>
    <nct_id>NCT04964583</nct_id>
  </id_info>
  <brief_title>Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19</brief_title>
  <acronym>Omehecatl</acronym>
  <official_title>Double-blind, Randomized, Prospective, Parallel Study to Demonstrate the Efficacy and Safety of Outpatient Treatment of the Fixed Combination of Hydroxychloroquine With Azithromycin Versus Hydroxychloroquine Treatment and Placebo Treatment in Patients Diagnosed With Mild COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ultra Laboratorios SA. de CV.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chloroquine and hydroxychloroquine are two antimalarial drugs that are also used in&#xD;
      autoimmune diseases. Chloroquine analogs have been shown to inhibit endosome acidification&#xD;
      and exhibit nonspecific antiviral activity at high micromolar concentration in vitro against&#xD;
      a wide range of emerging viruses (HIV, dengue, hepatitis C, chikungunya, influenza, Ebola,&#xD;
      SARS, and MERS ). virus) and more recently COVID-19. On the other hand, azithromycin is a&#xD;
      macrolide antibiotic indicated for infections caused by sensitive pathogens, but which in&#xD;
      combination with Hydroxychloroquine has shown a synergistic effect against the SARS-CoV-2&#xD;
      virus.&#xD;
&#xD;
      International studies show the lack of beneficial effect in hospitalized or mechanically&#xD;
      ventilated patients. Referring that because these medications reduce the in case of having a&#xD;
      beneficial effect it would be in the early onset, to avoid inflammation (cytokine storm), and&#xD;
      thus prevent hospitalizations.&#xD;
&#xD;
      The present study focuses on characterizing the possible synergy of the fixed combination of&#xD;
      hydroxychloroquine associated with azithromycin in the treatment of Covid-19 from mild to&#xD;
      moderate manifestations. Three treatment schemes are proposed with a 10-day follow-up, a) the&#xD;
      fixed combination of Hydroxychloroquine / Azithromycin (combination of interest), b)&#xD;
      Hydroxychloroquine (active comparison group) and c) non-active control group, using placebo.&#xD;
      A group of patients between 18 and 75 years old is considered, who may or may not present&#xD;
      other comorbidities. Follow-up will be carried out through quantification of viral load,&#xD;
      evaluation of the systemic inflammatory state, changes in clinical manifestations and&#xD;
      possible effect on the reduction of hospitalizations. Therefore, it is proposed to carry out&#xD;
      the following project.&#xD;
&#xD;
      objective To determine the efficacy and safety of Hydroxychloroquine / Azithromycin fixed&#xD;
      combination compared to Hydroxychloroquine or placebo in outpatients with Research design:&#xD;
      Phase II, multicenter, prospective, randomized, parallel, longitudinal, double-blind study.&#xD;
&#xD;
      Medications to use Group 1. Fixed combination of Hydroxychloroquine with Azithromycin 200 mg&#xD;
      / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg&#xD;
      one tablet every 12 hours for 5 more days.&#xD;
&#xD;
      Group 2. Hydroxychloroquine 200 mg, one tablet every 12 hours for ten days. Group 3. Placebo&#xD;
      one tablet every 12 hours for ten days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>15 days</time_frame>
    <description>Being admitted for hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>0 and 14 days</time_frame>
    <description>Measured by RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety</measure>
    <time_frame>21 days</time_frame>
    <description>any adverse event</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine with Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine 200 mg, one tablet every 12 hours for ten days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo one tablet every 12 hours for ten days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine with Azithromycin</intervention_name>
    <description>Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_label>Hydroxychloroquine with Azithromycin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Azithromycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given the signed informed consent form.&#xD;
&#xD;
          -  Confirmed diagnosis of COVID-19 infection by PCR with mild symptoms.&#xD;
&#xD;
          -  Patients who attend the primary care respiratory care module in the participating&#xD;
             units and who have symptoms suggestive of COVID-19, who comply with the current&#xD;
             operational definition.&#xD;
&#xD;
          -  With or without comorbidities such as hypertension, controlled diabetes mellitus,&#xD;
             cardiovascular or respiratory diseases.&#xD;
&#xD;
          -  Controlled diabetes will be considered to be that which is evidenced by results of&#xD;
             glycosylated hemoglobin less than 7% in the last 3 tables, whether it is reported in&#xD;
             your beneficiary file or by external laboratory results.&#xD;
&#xD;
          -  Electrocardiogram (ECG) normal or with variations without clinical relevance, with QT&#xD;
             interval &lt;450 ms.&#xD;
&#xD;
          -  No contraindication to study drugs (history of hypersensitivity to study drugs,&#xD;
             including macrolides, patients with renal failure (eGFR &lt;40 mL / min) or on renal&#xD;
             replacement therapy, patients with a history of retinopathy or macular degeneration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are participating in studies with investigational drugs.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  % Type II diabetes mellitus with glycated hemoglobin greater than 7%.&#xD;
&#xD;
          -  Patients requiring hospitalization or assisted mechanical ventilation&#xD;
&#xD;
          -  Cardiac disorders with cardiac conduction delay (QT segment ≥ 450 ms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UMF 28</name>
      <address>
        <city>Benito Juárez</city>
        <state>Mexico City</state>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivonne A Roy, MD</last_name>
      <phone>525522704760</phone>
      <email>ivonne3316@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Magaly A Ortiz Zamora, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lourdes G Navarro Susano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivonne A Roy García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación IMSS</name>
      <address>
        <city>Cuauhtémoc</city>
        <state>Mexico City</state>
        <zip>06600</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martha M Zapata Tarrés, MD</last_name>
      <phone>5554184099</phone>
    </contact>
    <investigator>
      <last_name>Marta M Zapata Tarrés, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Gutierrez Castrellón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romeo Rodríguez Suárez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMF 52</name>
      <address>
        <city>Cuautitlán Izcalli</city>
        <state>State Of Mexico</state>
        <zip>54720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moises Moreno, MD</last_name>
      <phone>5565593877</phone>
      <email>sesby14@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Miroslava Guzmán Rivas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moises Moreno Noguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Rodolfo Rivas Ruiz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Database with all non identifiable data will be available upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>6 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

